OBJECTIVE

To investigate the clinical value of Fuzheng Guben anticancer decoction combined with taxol in treating ovarian carcinoma (OC).

METHODS

The medical records of 80 OC patients treated in the First People's Hospital of Fuyang Hangzhou (January 2018-January 2021) were retrospectively analyzed, and the patients were split into the control group and the experimental group according to the treatment regimen, with 40 cases each. Those in the control group accepted the taxol chemotherapy, and on this basis, those in the experimental group took the Fuzheng Guben anticancer decoction, so as to compare its clinical efficacy and complication incidence.

RESULTS

No statistical between-group differences in patients' general information were observed ( > 0.05); compared with the control group, the disease objective remission rate of the experimental group was greatly higher ( < 0.05); before and after treatment, the changes in CD8 were not significant, indicating no statistically significant between-group differences ( > 0.05), and after treatment, CD3, CD4, and CD4/CD8 were obviously higher than before and were obviously higher in the experimental group than in the control group ( < 0.05); after treatment, the CA125, CA199, and CEA levels were obviously lower than before and were significantly lower in the experimental group than in the control group ( < 0.05); the mean survival of the experimental group was significantly higher than that of the control group (19.80 ± 5.84 vs. 14.075 ± 5.12 months, < 0.05); and between the two groups, the incidence rate of adverse reactions of the experimental group was remarkably lower ( < 0.05).

CONCLUSION

On the basis of taxol chemotherapy, jointly applying Fuzheng Guben anticancer decoction can significantly improve the clinical efficacy of OC, help to improve patients' immune function, lower the complication incidence rate, and prolong the mean survival.